Austin · Hybrid
Mindbloom
Work at Mindbloom?
About Mindbloom
Mindbloom, founded in 2018, aims to transform lives to transform the world. It positions itself as the #1 trusted brand in psychedelic therapy and the first and largest national provider of ketamine therapy for depression, anxiety, and PTSD. The company conducts over 300,000 treatments annually and operates in 38 states, reaching 86% of Americans. Mindbloom has produced the two largest peer-reviewed studies in psychedelic medicine history and plans to offer next-generation psychedelic medicines, including MDMA and psilocybin.
Open positions · 3
Austin · Hybrid
United States · Remote solely
Company at a glance
Investors
Location
Life at Mindbloom
Frequently asked questions
Companies similar to Mindbloom
Building brands, Creating new relationships, Adding value to our clients
ABC Solutions enables companies to hire and manage dedicated teams in the Philippines and Colombia without establishing a local entity, handling the full employment lifecycle from recruiting to payroll and compliance. By delivering end-to-end HR and payroll support, ABC accelerates global delivery while maintaining local compliance and seamless team operations. This streamlined offshore staffing solution helps clients scale quickly with expert regional know-how.
Aira is an AI platform designed for procedural specialties that serves as the payer intelligence layer for medical device companies and surgical practices. The company automates critical back-office workflows while handling the full payer compliance lifecycle, including benefits verification, medical necessity determinations, prior authorization, and appeals management. By functioning as the intelligence layer powering market access teams, Aira helps healthcare providers and device manufacturers navigate the complexity of reimbursement processes to increase patient access to needed procedures. The platform addresses a key pain point in healthcare operations by streamlining the administrative burden that often delays care and complicates market entry for medical innovations.
